S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Sangamo Therapeutics Stock Forecast, Price & News

+0.14 (+3.38%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.25 million shs
Average Volume
1.55 million shs
Market Capitalization
$627.82 million
P/E Ratio
Dividend Yield
Price Target

Sangamo Therapeutics Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.50 Rating Score
221.3% Upside
$13.75 Price Target
Short Interest
10.31% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Acquiring Shares
$25.03 K Bought Last Quarter
Proj. Earnings Growth
From ($1.42) to ($1.43) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.77 out of 5 stars

Medical Sector

777th out of 1,428 stocks

Biological Products, Except Diagnostic Industry

121st out of 217 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Sangamo Therapeutics logo

About Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

SGMO Stock News Headlines

NRDS, PTGX and SGMO are among after hour movers
Sangamo Therapeutics Tops Q1 EPS by 1c
Sangamo Therapeutics Q1 2022 Earnings Preview
Sangamo Therapeutics's Earnings: A Preview
Sangamo Therapeutics: Q4 Earnings Insights
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$-178.29 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$110.70 million
Book Value
$2.58 per share


Free Float
Market Cap
$627.82 million

Social Links

Sangamo Therapeutics Frequently Asked Questions

Should I buy or sell Sangamo Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Sangamo Therapeutics stock.
View analyst ratings for Sangamo Therapeutics
or view top-rated stocks.

What is Sangamo Therapeutics' stock price forecast for 2022?

4 Wall Street analysts have issued 12 month price objectives for Sangamo Therapeutics' stock. Their SGMO stock forecasts range from $5.00 to $25.00. On average, they expect Sangamo Therapeutics' share price to reach $13.75 in the next year. This suggests a possible upside of 221.3% from the stock's current price.
View analysts' price targets for Sangamo Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Sangamo Therapeutics' stock price performed in 2022?

Sangamo Therapeutics' stock was trading at $7.50 on January 1st, 2022. Since then, SGMO shares have decreased by 42.9% and is now trading at $4.28.
View the best growth stocks for 2022 here

When is Sangamo Therapeutics' next earnings date?

Sangamo Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Sangamo Therapeutics

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) released its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.02. The biopharmaceutical company earned $28.20 million during the quarter, compared to analysts' expectations of $27.29 million. Sangamo Therapeutics had a negative net margin of 156.53% and a negative trailing twelve-month return on equity of 45.17%. The business's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.32) EPS.
View Sangamo Therapeutics' earnings history

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the following people:
  • Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D., CEO, Pres & Director (Age 59, Pay $1.14M)
  • Ms. Prathyusha Duraibabu CPA, M.B.A., Sr. VP, CFO & Principal Accounting Officer (Age 43, Pay $495.58k)
  • Mr. D. Mark McClung, Exec. VP & COO (Age 59, Pay $617.96k)
  • Dr. R. Andrew Ramelmeier Ph.D., Exec. VP of Technical Operations (Age 60, Pay $651.27k)
  • Dr. Robert J. Schott M.P.H., M.D., MPH, FACC, Sr. VP & Head of Devel. (Age 64, Pay $628.87k)
  • Dr. Jason D. Fontenot Ph.D., Sr. VP & Chief Scientific Officer (Age 52)
  • Ms. Aron Feingold, Head of Corp. Communications & Investor Relations Officer
  • Mr. Scott B. Willoughby, Sr. VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Ms. Whitney Jones, Sr. VP & Chief People Officer
  • Dr. Nathalie Dubois-Stringfellow, Sr. VP of Product Devel. & Management

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics CEO Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among Sangamo Therapeutics' employees.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $4.28.

How much money does Sangamo Therapeutics make?

Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $627.82 million and generates $110.70 million in revenue each year. The biopharmaceutical company earns $-178.29 million in net income (profit) each year or ($1.220010) on an earnings per share basis.

How many employees does Sangamo Therapeutics have?

Sangamo Therapeutics employs 431 workers across the globe.

When was Sangamo Therapeutics founded?

Sangamo Therapeutics was founded in 1995.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for Sangamo Therapeutics is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951.

This page (NASDAQ:SGMO) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.